These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25371286)

  • 1. Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network.
    Marchesi F; Cerchiara E; Dessanti ML; Gumenyuk S; Franceschini L; Palombi F; Pisani F; Romano A; Spadea A; Pupo L; Annibali O; La Malfa A; Arcese W; Mengarelli A
    Br J Haematol; 2015 Apr; 169(2):293-6. PubMed ID: 25371286
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
    Marchesi F; Mengarelli A
    Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
    Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
    Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
    Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
    Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
    Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.
    Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D
    Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
    Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
    Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.
    Marchesi F; Terrenato I; Papa E; Tomassi M; Falcucci P; Gumenyuk S; Palombi F; Pisani F; Renzi D; Romano A; Spadea A; Regazzo G; Rizzo MG; De Rienzo M; Ripellino C; Sgromo S; Viggiani C; Ponte E; Kayal R; Cordone I; Foddai ML; Mengarelli A
    Ann Hematol; 2024 Mar; 103(3):947-956. PubMed ID: 38189833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.
    Schmitt M; Hoffmann JM; Lorenz K; Publicover A; Schmitt A; Nagler A
    Vox Sang; 2016 Aug; 111(2):178-86. PubMed ID: 27509033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Mobilization and Transplantation.
    León-González M; León-Peña AA; Vallejo-VIllalobos MF; Núñez-Cortés AK; Ruiz-Argüelles A; Ruiz-Argüelles GJ
    Rev Invest Clin; 2016; 68(4):181-3. PubMed ID: 27623036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.
    Martino M; Gori M; Porto G; Pellicano M; Santoro L; Verduci C; Canale FA; Loteta B; Moscato T; Alati C; Ieracitano MC; Cuzzocrea A; Altomonte M; Florenzano MT; Morabito A; Irrera G; Naso V; Pugliese M; Console G; Ferreri A; Imbalzano L; Tripepi G; Pitino A
    Ann Hematol; 2023 Jul; 102(7):1915-1925. PubMed ID: 37079070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.
    Ianotto JC; Ngo Sack F; Couturier MA; Tempescul A; Mugnier N; Delepine P; Guillerm G; Berthou C
    Leuk Lymphoma; 2014 Jan; 55(1):74-7. PubMed ID: 23566160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biosimilar filgrastim: from development to record].
    García Alfonso P
    Farm Hosp; 2010 Mar; 34 Suppl 1():19-24. PubMed ID: 20920854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar biologics: never identical but close enough.
    Abi-Raad R; Smith BR
    Transfusion; 2015 Feb; 55(2):229-31. PubMed ID: 25683185
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
    Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
    Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
    BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only.
    Nicol C; Henry C; Couturier MA; Delépine P; Tripogney C; Buors C; Guillerm G; Berthou C; Tempescul A; Ianotto JC
    Leuk Lymphoma; 2017 Sep; 58(9):1-3. PubMed ID: 28278727
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
    Kim IH; Park SK; Suh OK; Oh JM
    Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.